Ruxolitinib, nke a makwaara dị ka ruxolitinib na China, bụ otu n'ime "ọgwụ ọhụrụ" nke edepụtara n'ọtụtụ ebe na ntuziaka ụlọ ọgwụ maka ọgwụgwọ ọrịa hematological na afọ ndị na-adịbeghị anya, ma gosi na ọ dị irè na ọrịa myeloproliferative.
Ọgwụ ezubere iche bụ Jakavi ruxolitinib nwere ike igbochi ọrụ nke ọwa JAK-STAT niile ma belata akara ngosi nke ọwa ahụ na-abawanye nke ọma, wee nweta nrụpụta ọrụ.Enwere ike iji ya mee ihe maka ọgwụgwọ ọrịa dị iche iche, yana maka mmebi saịtị JAK1.
Ruxolitinibbụ kinase inhibitor egosiri maka ọgwụgwọ ndị ọrịa nwere myelofibrosis nke etiti ma ọ bụ nnukwu ihe ize ndụ, gụnyere myelofibrosis nke mbụ, post-geniculocytosis myelofibrosis, na post-primary thrombocythemia myelofibrosis.
Ọmụmụ ihe ọmụmụ ụlọ ọgwụ yiri nke ahụ (n = 219) ndị ọrịa na-enweghị usoro nke nwere etiti-ihe ize ndụ-2 ma ọ bụ nnukwu ihe ize ndụ MF mbụ, ndị ọrịa nwere MF mgbe ezi erythroblastosis gasịrị, ma ọ bụ ndị ọrịa nwere MF mgbe thrombocytosis bụ isi na otu abụọ, otu na-anata ruxolitinib ọnụ 15 ruo 20 mgbid. (n=146) na nke ọzọ na-anata ọgwụ nchịkwa dị mma (n=73).Isi na isi njedebe nke abụọ nke ọmụmụ ihe ahụ bụ pasent nke ndị ọrịa nwere ≥35% mbelata nke splin (nke a na-enyocha site na imaging resonance magnet ma ọ bụ computed tomography) na izu 48 na 24, n'otu n'otu.Nsonaazụ gosiri na pasent nke ndị ọrịa nwere ihe karịrị 35% mbelata nke splin olu site na mmalite na izu 24 bụ 31.9% na otu ọgwụgwọ ma e jiri ya tụnyere 0% na otu njikwa (P <0.0001);na pasent nke ndị ọrịa nwere ihe karịrị 35% mbelata ụda splin site na mmalite na izu 48 bụ 28.5% na otu ọgwụgwọ ma e jiri ya tụnyere 0% na otu njikwa (P <0.0001).Na mgbakwunye, ruxolitinib belatara mgbaàmà n'ozuzu ya ma mee ka ndụ dịkwuo mma na ndị ọrịa.Dabere na nsonaazụ ule ụlọ ọgwụ abụọ a,ruxolitinibghọrọ ọgwụ izizi nke US FDA kwadoro maka ọgwụgwọ ndị ọrịa nwere MF.